Login / Signup

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.

Maria E Suarez-AlmazorXerxes PundoleNoha Abdel-WahabDouglas B JohnsonDipti GuptaIlya GlezermanTim CooksleyRonald AndersonAda BlidnerJennifer ChoiMichael DouganPamela GinexMonica GirotraVickie R ShannonBernardo Leon Rapoport
Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)
Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.
Keyphrases